The antitumour efficacy and survival rate improvement of this triple combination therapy is due to the more effective activation of the cGAS/STING signalling pathway by AZD6738, which is conducive to the synergistic effect between radiotherapy and anti-PD-L1, and this triple combination therapy can generate stronger immune memory and persistent antitumour immunity, thereby preventing tumour recurrence [118]. This evidence concerns the gene CD274 and neoplasm.